eligible patients should explore NICE-approved options such as semaglutide 2.4 mg (Wegovy) or tirzepatide (Mounjaro)
doi:10.1055/s-0041-1731035 References: 1
The third consideration is risk management and longterm outcomes
Hashimotos disease risk factors include: Being female Age 30 to 50 Genetics, family history Other autoimmune diseases Pregnancy-related immunity and hormonal changes Radiation or toxin exposure How do I get tested for Hashimotos disease
According to a Rybelsus trial published in the The New England Journal of Medicine: 44% of users reported nausea 32% of users reported diarrhea Key takeaway Early evidence showed that Pfizers new oral GLP-1 receptor agonist danuglipron showed similar results to Novos Ozempic without the need for injection, and to its oral formulation Rybelsus without the need for fasting restrictions
Regulatory status as of July 25, 2026: The FDA Pharmacy Compounding Advisory Committee recommended BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for inclusion on the 503A Bulks List
